A phase IIa, 28-day treatment, multi-center, randomized, comparator-controlled, observer-blind trial with intra-individual left/right comparison to investigate the anti-psoriatic efficacy and the safety of an LAS41004 formulation in comparison to an active reference in patients with mild to moderate plaque psoriasis

Trial Profile

A phase IIa, 28-day treatment, multi-center, randomized, comparator-controlled, observer-blind trial with intra-individual left/right comparison to investigate the anti-psoriatic efficacy and the safety of an LAS41004 formulation in comparison to an active reference in patients with mild to moderate plaque psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Betamethasone dipropionate/bexarotene (Primary) ; Betamethasone-dipropionate/calcipotriol
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Almirall Hermal GmbH
  • Most Recent Events

    • 15 Nov 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 13 May 2014 32646
    • 13 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top